CG
ACAD icon

Clinton Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Clinton Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-28,707
Closed -$932K – 880
2016
Q2 		$932K Buy
+28,707
New +$961K 0.04% 507

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Clinton Group's ACAD Position: Q3 2016 in Review

Clinton Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2016, closing a stake of 28,707 shares — an estimated $932K sold.

Clinton Group first reported a position in ACAD in Q2 2016 and held it in 1 quarter. The position peaked at $932K in Q2 2016. 234 funds tracked by Wall St. Rank hold ACAD as of Q3 2016.

  • Clinton Group reported no remaining Acadia Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Clinton Group sold 28,707 Acadia Pharmaceuticals shares in Q3 2016, an estimated $932K.
  • Clinton Group first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Clinton Group's Acadia Pharmaceuticals position peaked at $932K in Q2 2016.
  • 234 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2016.

Based on Clinton Group's 13F filing for Q3 2016, filed 14 Nov 2016.